Cwm LLC Increases Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Cwm LLC grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 18.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,584 shares of the company’s stock after acquiring an additional 410 shares during the quarter. Cwm LLC’s holdings in Dr. Reddy’s Laboratories were worth $190,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Aikya Investment Management Ltd purchased a new position in shares of Dr. Reddy’s Laboratories in the fourth quarter worth approximately $75,850,000. Assenagon Asset Management S.A. boosted its holdings in shares of Dr. Reddy’s Laboratories by 416.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 196,146 shares of the company’s stock worth $13,648,000 after buying an additional 158,141 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Dr. Reddy’s Laboratories by 319.2% in the third quarter. Qube Research & Technologies Ltd now owns 174,398 shares of the company’s stock worth $11,662,000 after buying an additional 132,791 shares during the last quarter. Schroder Investment Management Group boosted its holdings in shares of Dr. Reddy’s Laboratories by 77.6% in the fourth quarter. Schroder Investment Management Group now owns 266,653 shares of the company’s stock worth $18,554,000 after buying an additional 116,488 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 126.5% in the fourth quarter. Fisher Asset Management LLC now owns 205,280 shares of the company’s stock worth $14,283,000 after buying an additional 114,630 shares during the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

RDY opened at $71.56 on Friday. The firm has a market cap of $11.94 billion, a P/E ratio of 17.76, a PEG ratio of 1.59 and a beta of 0.52. Dr. Reddy’s Laboratories Limited has a 1-year low of $60.10 and a 1-year high of $77.72. The company has a 50 day simple moving average of $71.13 and a two-hundred day simple moving average of $71.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.58 and a quick ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.08. The business had revenue of $850.00 million during the quarter, compared to analyst estimates of $825.20 million. Dr. Reddy’s Laboratories had a net margin of 19.97% and a return on equity of 21.32%. Equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RDY. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 16th. Barclays upped their price target on shares of Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.